Celcuity Inc. (CELC)

Name: Celcuity Inc. (CELC) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Celcuity Inc. (CELC)

Stock Card

$88.44

$-4.80 (-5.15%)

As on 28-Aug-2026 16:00EDT

Market cap

$4,328 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

78.9

Div. Yield

0 %

Celcuity (CELC) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 88.23 High: 92.48

52 Week Range

Low: 44.42 High: 151.02

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-14.3 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-7.8
Debt to Equity

0
Book Value

$-0.3
EPS

$-4.4
Face value

--
Shares outstanding

48,931,908

9 Years Aggregate

CFO

$-139.17 Mln

EBITDA

$-168.27 Mln

Net Profit

$-171.11 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Celcuity (CELC)	-11.3	7.5	-34.0	77.0	107.6	31.9	--
BSE Sensex	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Celcuity (CELC)	662.0	-10.1	4.0	6.2	44.0	-13.9	-55.6
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Celcuity (CELC)	88.4	4,327.5	0.2	-226.5	-84,916.9	--	--	78.9
Arrowhead Pharmaceuticals (ARWR)	84.9	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	247.9	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	72.1	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	105.4	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	351.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	533.8	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	600.7	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	344.8	9,625.4	0.0	-339.1	--	-30.6	--	7.6

Shareholding Pattern

View Details

About Celcuity (CELC)

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets... various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota. Read more

Co-Founder, Chairman & CEO

Mr. Brian F. Sullivan
Co-Founder, Chairman & CEO

Mr. Brian F. Sullivan
Headquarters

Minneapolis, MN
Website

https://www.celcuity.com

FAQs for Celcuity (CELC)

What is the current share price of Celcuity Inc (CELC) Today?

The share price of Celcuity Inc (CELC) is $88.44 (NASDAQ) as of 28-Aug-2026 16:00 EDT. Celcuity Inc (CELC) has given a return of 107.56% in the last 3 years.

What is the current PB & PE ratio of Celcuity Inc (CELC)?

Since, TTM earnings of Celcuity Inc (CELC) is negative, P/E ratio is not available.
The P/B ratio of Celcuity Inc (CELC) is 78.90 times as on 28-Aug-2026, a 1375 premium to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.